Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Sloss, Callum M

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Aug 2008 - 5116-23 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural

1078-0432

10.1158/1078-0432.CCR-07-4506 doi


Adenocarcinoma--drug therapy
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Apoptosis--drug effects
Bevacizumab
Blotting, Western
Boronic Acids--administration & dosage
Bortezomib
Cell Line, Tumor
Cetuximab
Deoxycytidine--administration & dosage
ErbB Receptors--drug effects
Erlotinib Hydrochloride
Female
Humans
Lactones--administration & dosage
Mice
Mice, Nude
Pancreatic Neoplasms--drug therapy
Phosphatidylinositol 3-Kinases--drug effects
Protease Inhibitors--therapeutic use
Proteasome Inhibitors
Pyrazines--administration & dosage
Pyrroles--administration & dosage
Quinazolines--administration & dosage
Signal Transduction--drug effects
Xenograft Model Antitumor Assays
Gemcitabine